Carlo Bifulco

46.7k total citations · 2 hit papers
106 papers, 3.7k citations indexed

About

Carlo Bifulco is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Carlo Bifulco has authored 106 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 68 papers in Oncology, 43 papers in Immunology and 15 papers in Molecular Biology. Recurrent topics in Carlo Bifulco's work include Cancer Immunotherapy and Biomarkers (40 papers), Immunotherapy and Immune Responses (33 papers) and CAR-T cell therapy research (19 papers). Carlo Bifulco is often cited by papers focused on Cancer Immunotherapy and Biomarkers (40 papers), Immunotherapy and Immune Responses (33 papers) and CAR-T cell therapy research (19 papers). Carlo Bifulco collaborates with scholars based in United States, Italy and France. Carlo Bifulco's co-authors include Bernard A. Fox, Rom S. Leidner, Carlo Parravicini, R. Bryan Bell, Elisa Feudale, Franco Rilke, Fred H. Reynolds, Giorgio Cattoretti, Elena Sabattini and Johannes Gerdes and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Carlo Bifulco

102 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Antigen unmasking on formalin‐fixed, paraffin‐embedded tissue sections

1993 625 citations Carlo Bifulco et al. profile →
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)

2019 491 citations R. Bryan Bell, Carlo Bifulco et al. Journal for ImmunoTherapy of Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Carlo Bifulco United States	29	1.8k	1.1k	785	448	355	106	3.7k
Zhensheng Liu China	39	1.3k 0.7×	372 0.3×	2.0k 2.5×	567 1.3×	299 0.8×	221	4.7k
Marcel G.J. Tilanus Netherlands	35	732 0.4×	2.0k 1.8×	889 1.1×	197 0.4×	304 0.9×	182	4.2k
Michael S. Rooney United States	14	2.3k 1.3×	2.0k 1.7×	2.0k 2.6×	1.0k 2.3×	340 1.0×	18	4.7k
Hiroyuki Suzuki Japan	27	911 0.5×	393 0.3×	518 0.7×	628 1.4×	235 0.7×	229	3.0k
Lars‐Erik Holm Sweden	42	680 0.4×	224 0.2×	800 1.0×	418 0.9×	663 1.9×	135	5.5k
Masahiro Nakashima Japan	34	1.1k 0.6×	1.0k 0.9×	1.7k 2.2×	380 0.8×	525 1.5×	208	5.3k
Pedro L. Fernández Spain	47	2.1k 1.2×	850 0.8×	2.8k 3.5×	984 2.2×	765 2.2×	184	6.5k
Masahiko Ohsawa Japan	49	2.5k 1.4×	829 0.7×	947 1.2×	1.2k 2.8×	869 2.4×	292	7.2k
Patrick M. Gaffney United States	46	1.1k 0.6×	3.4k 3.0×	2.4k 3.1×	176 0.4×	204 0.6×	158	8.4k
Patrizia Comoli Italy	45	2.9k 1.6×	1.3k 1.2×	423 0.5×	198 0.4×	565 1.6×	163	5.7k

Countries citing papers authored by Carlo Bifulco

Since Specialization

Citations

This map shows the geographic impact of Carlo Bifulco's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carlo Bifulco with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carlo Bifulco more than expected).

Fields of papers citing papers by Carlo Bifulco

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carlo Bifulco. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carlo Bifulco. The network helps show where Carlo Bifulco may publish in the future.

Co-authorship network of co-authors of Carlo Bifulco

This figure shows the co-authorship network connecting the top 25 collaborators of Carlo Bifulco. A scholar is included among the top collaborators of Carlo Bifulco based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carlo Bifulco. Carlo Bifulco is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tran, Thuy, Lais Osmani, Marta Piecychna, et al.. (2025). Improving immunotherapy responses by dual inhibition of macrophage migration inhibitory factor and PD-1. JCI Insight. 10(20).

Wong, Cliff, Zelalem Gero, Jaspreet Bagga, et al.. (2025). TRIALSCOPE — A Framework for Clinical Trial Simulation from Real-World Data. NEJM AI. 2(10). 2 indexed citations

Vita, Alessandro De, Douglas Hanes, Bela Bapat, et al.. (2024). Clinical impact for advanced non-small-cell lung cancer patients tested using comprehensive genomic profiling at a large USA health care system. SHILAP Revista de lepidopterología. 5. 100057–100057. 2 indexed citations

Bapat, Bela, Douglas Hanes, Shu‐Ching Chang, et al.. (2024). Widespread Adoption of Precision Anticancer Therapies After Implementation of Pathologist-Directed Comprehensive Genomic Profiling Across a Large US Health System. JCO Oncology Practice. 20(11). 1523–1532. 2 indexed citations

Bifulco, Carlo, et al.. (2024). Digital Pathology for Better Clinical Practice. Cancers. 16(9). 1686–1686. 19 indexed citations

Knorr, David A., Lucas Blanchard, Rom S. Leidner, et al.. (2023). FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment. Cancer Immunology Research. 12(3). 322–333. 18 indexed citations

Ascierto, Paolo A., Carlo Bifulco, Fortunato Ciardiello, et al.. (2021). Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd–3rd, 2020, Italy). Journal of Translational Medicine. 19(1). 238–238. 3 indexed citations

Duhen, Rebekka, Carmen Ballesteros‐Merino, Alexandra K. Frye, et al.. (2021). Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells. Nature Communications. 12(1). 1047–1047. 114 indexed citations

Leidner, Rom S., Marka R. Crittenden, Kristina H. Young, et al.. (2021). Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma. Journal for ImmunoTherapy of Cancer. 9(5). e002485–e002485. 120 indexed citations

10.

Bethmann, Daniel, Zipei Feng, Shu‐Ching Chang, et al.. (2020). Cumulative suppressive index as a predictor of relapse free survival and overall survival in Human Papilloma Virus‐negative oral squamous cell carcinomas with negative resection margins. Head & Neck. 43(2). 568–576. 6 indexed citations

11.

Ascierto, Paolo A., Carlo Bifulco, Claus Garbe, et al.. (2020). The Great Debate at ‘Immunotherapy Bridge’, Naples, December 5, 2019. Journal for ImmunoTherapy of Cancer. 8(2). e000921–e000921. 2 indexed citations

12.

Ascierto, Paolo A., Carlo Bifulco, Giuseppe Palmieri, Solange Peters, & Nikoletta Sidiropoulos. (2019). Preanalytic Variables and Tissue Stewardship for Reliable Next-Generation Sequencing (NGS) Clinical Analysis. Journal of Molecular Diagnostics. 21(5). 756–767. 35 indexed citations

13.

Madonna, Gabriele, Carmen Ballesteros‐Merino, Zipei Feng, et al.. (2017). PD-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab. OncoImmunology. 7(12). e1405206–e1405206. 46 indexed citations

14.

Rettig, Michael P., John E. Godwin, Norbert Vey, et al.. (2017). Preliminary Translational Results from an Ongoing Phase 1 Study of Flotetuzumab, a CD123 x CD3 Dart®, in AML/MDS: Rationale for Combining Flotetuzumab and Anti-PD-1/PD-L1 Immunotherapies. Blood. 130. 1365–1365. 10 indexed citations

15.

Stahl, Kerstin, Irene Kohn, Veit Blauhut, et al.. (2016). Impacts of European drought events: insights from an international database of text-based reports. Natural hazards and earth system sciences. 16(3). 801–819. 209 indexed citations

16.

Lavotshkin, Simon, Hitoe Torisu‐Itakura, Junko Ozao‐Choy, et al.. (2015). Immunoprofiling for Prognostic Assessment of Colon Cancer: a Novel Complement to Ultrastaging. Journal of Gastrointestinal Surgery. 19(6). 999–1006. 15 indexed citations

17.

Graff, Julie N., Sachin Puri, Carlo Bifulco, Bernard A. Fox, & Tomasz M. Beer. (2014). Sustained Complete Response to CTLA-4 Blockade in a Patient with Metastatic, Castration-Resistant Prostate Cancer. Cancer Immunology Research. 2(5). 399–403. 29 indexed citations

18.

Bifulco, Carlo, et al.. (2008). Tumor Growth-Promoting Properties of Macrophage Migration Inhibitory Factor. Current Pharmaceutical Design. 14(36). 3790–3801. 58 indexed citations

19.

Iyer, Anita, Marie E. Robert, Carlo Bifulco, Ronald R. Salem, & Dhanpat Jain. (2008). Different cytokeratin and neuronal cell adhesion molecule staining patterns in focal nodular hyperplasia and hepatic adenoma and their significance. Human Pathology. 39(9). 1370–1377. 20 indexed citations

20.

Magni, Michele, Massimo Di Nicola, Carmelo Carlo‐Stella, et al.. (2002). Identical rearrangement of immunoglobulin heavy chain gene in neoplastic Langerhans cells and B-lymphocytes: evidence for a common precursor. Leukemia Research. 26(12). 1131–1133. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact